乳腺癌根治术或改良根治术后辅助性放疗

doi:10.3760/cma.j.issn.1673-422X.2016.05.014

摘要/Abstract

摘要： 近年来关于影响乳腺癌术后辅助性放疗预后及效果的因素逐渐成为研究热点，乳腺癌的不同分期、不同亚型、激素水平以及患者的身体质量指数等均与其密切相关。此外，从三维适形放疗到螺旋断层放疗，放疗技术的发展也有了质的突破，使得疾病的治疗更加精确化、合理化。

关键词: 乳腺肿瘤, 乳房切除术, 根治性, 乳房切除术, 改良根治性, 放射疗法

Abstract: In recent years, the influencing factors of prognosis and effect after radiotherapy in breast cancer patients with radical mastectomy or modified radical mastectomy have gradually become a hot research, and it is closely related with the stages, subtypes, hormone levels and the body mass index (BMI). Otherwise, from three dimensional conformal radiation therapy to helical tomotherapy, the development of radiation technology has a breakthrough progress and makes the treatment of diseases more accurate and rational.

Key words: Breast neoplasms, Mastectomy, radical, Mastectomy, modified radical, Radiotherapy

孙颖，张海波，阎英. 乳腺癌根治术或改良根治术后辅助性放疗[J]. 国际肿瘤学杂志, 2016, 43(5): 376-378.

Sun Ying, Zhang Haibo, Yan Ying. Adjuvant radiotherapy in breast cancer patients after radical mastectomy or modified radical mastectomy[J]. Journal of International Oncology, 2016, 43(5): 376-378.

参考文献

［1］ Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008［J］. Int J Cancer, 2010, 127(12): 2893-2917. DOI: 10.1002/ijc.25516. ［2］惠周光, 张烨, 张江鹄, 等. 2010年与2004年中国大陆地区乳腺癌改良根治术后放疗现状比较［J］. 中华放射肿瘤学杂志, 2012, 21(4): 352-356. DOI: 10.3760/cma.j.issn.10044221.2012.04.018. ［3］ Truong PT, Olivotto IA, Kader HA, et al. Selecting breast cancer patients with T1T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy［J］. Int J Radiat Oncol Biol Phys, 2005, 61(5): 1337-1347. DOI: 10.1016/j.ijrobp.2004.08.009. ［4］ Sharma R, Bedrosian I, Lucci A, et al. Presentday locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy［J］. Ann Surg Oncol, 2010, 17(11): 2899-2908. DOI: 10.1245/s104340101089x. ［5］ Yang PS, Chen CM, Liu MC, et al. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status［J］. Int J Radiat Oncol Biol Phys, 2010, 77(2): 516-522. DOI: 10.1016/j.ijrobp.2009.05.016. ［6］ Hamamoto Y, Ohsumi S, Aogi K, et al. Are there highrisk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy?［J］. Breast Cancer, 2014, 21(2): 177-182. DOI: 10.1007/s1228201203697. ［7］王淑莲, 余子豪, 宋永文,等. ER和PR及Her2对改良根治术后腋窝淋巴结阳性乳腺癌放疗疗效的影响［J］.中华放射肿瘤学杂志, 2010, 19(4): 307-310. DOI: 10.3760/cma.j.issn.1673422X.2014.01.021. ［8］谢源福, 吴秀萍, 卓延红, 等. 改良根治术后腋窝淋巴结阳性乳腺癌放疗效果与ER、PR及HER2相关性分析［J］. 国际肿瘤学杂志, 2014, 41(1): 66-69. DOI: 10.3760/cma.j.issn.10044221.2010.04.009. ［9］ Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse［J］. J Clin Oncol, 2010, 28(10): 1684-1691. DOI: 10.1200/JCO.2009.24.9284. ［10］ Al Saeed EF, Ghabbban AJ, Tunio MA. Impact of BMI on locoregional control among saudi patients with breast cancer after breast conserving surgery and modified radical mastectomy［J］. Gulf J Oncolog, 2015, 1(17): 7-14. ［11］ Opp D, Forster K, Li W, et al. Evaluation of bolus electron conformal therapy compared with conventional techniques for the treatment of left chest wall postmastectomy in patients with breast cancer［J］. Med Dosim, 2013, 38(4): 448-453. DOI: 10.1016/j.meddos.2013.08.002. ［12］ Surucu M, Klein EE, MamaluiHunter M, et al. Planning tools for modulated electron radiotherapy［J］. Med Phys, 2010, 37(5): 2215-2224. ［13］ Wright P, Suilamo S, Lindholm P, et al. Isocentric integration of intensitymodulated radiotherapy with electron fields improves field junction dose uniformity in postmastectomy radiotherapy［J］. Acta Oncol, 2014, 53(8): 1019-1026. DOI: 10.3109/0284186X.2014.926027. ［14］章倩, 陈佳艺, 胡伟刚, 等.左侧乳腺癌改良根治术后胸壁和内乳区三维适形和调强放疗计划剂量学研究［J］. 中国临床医学, 2010, 17(3): 445-448. DOI: 10.3969/j.issn.10086358.2010.03.053. ［15］ Rudat V, Alaradi AA, Mohamed A, et al. Tangential beam IMRT versus tangential beam 3DCRT of the chest wall in postmastectomy breast cancer patients: a dosimetric comparison［J］. Radiat Oncol, 2011, 6: 26. DOI: 10.1186/1748717X626. ［16］马金利, 李炯雁, 朱传营, 等. 乳腺癌改良根治术后胸壁和区域淋巴引流区整体化调强放疗剂量学与不良反应分析［J］. 中华放射肿瘤学志, 2012, 21(1): 47-51. DOI: 10.3760/cma.j.issn.10044221.2012.01.014. ［17］周桂霞, 戴相昆, 徐寿平, 等. 乳腺癌术后放疗3种治疗计划的剂量学研究［J］. 中华放射医学与防护杂志, 2010, 30(3): 314-316. ［18］ Nichols GP, Fontenot JD, Gibbons JP, et al. Evaluation of volumetric modulated arc therapy for postmastectomy treatment［J］. Radiat Oncol, 2014, 9: 66. DOI: 10.1186/1748717X966. ［19］ Jia MM, Liang ZJ, Chen Q, et al. Effects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with positive axillary lymph nodes［J］. Cancer Biol Med, 2014, 11(2): 123-129. DOI: 10.7497/j.issn.20953941.2014.02.007. ［20］ Darby SC, Mcgale P, Taylor CW, et al. Longterm mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries［J］. Lancet Oncol, 2005, 6(8): 557-565. DOI: 10.1016/S14702045(05)702515.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[4]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[5]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[6]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[7]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[8]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[9]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[10]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[11]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[12]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[13]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[14]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[15]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.